Nyxoah's Exciting Participation in Healthcare Conference
Nyxoah SA (Euronext Brussels/NASDAQ: NYXH), a pioneering medical technology company, is gearing up for an important event. The management team will engage in a fireside chat during the Piper Sandler 37th Annual Healthcare Conference, scheduled for December 4. This is a valuable platform for the company to discuss their innovative strategies and advancements in treating Obstructive Sleep Apnea (OSA).
Details of the Conference
The fireside chat is set to commence at 1:30 p.m. (ET) and will be available through a live audio webcast, offering investors and interested parties a chance to gain insights directly from the management team. Nyxoah is dedicated to keeping its stakeholders informed about their ongoing efforts in the medical technology arena, particularly in neuromodulation solutions for OSA.
About Nyxoah and Its Vision
Nyxoah has established itself as a leader in creating groundbreaking treatment options for patients suffering from obstructive sleep apnea, a condition that can lead to severe health complications. The company's flagship product, the Genio system, exemplifies their commitment to innovation. This device offers a unique leadless and battery-free hypoglossal neurostimulation therapy, specifically designed for OSA patients.
The Genio System: Transforming Patient Care
At the heart of Nyxoah's vision is the belief that every OSA patient deserves restful nights and the ability to fully engage in their lives. The Genio system is a patient-centric solution that is reshaping the landscape of sleep disorder therapies. By utilizing neuromodulation, Nyxoah offers a viable alternative for those who have not found success with traditional treatments.
Recent Advancements and Achievements
Nyxoah's journey has been marked by significant milestones. After the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019, paving the way for broader access to this innovative therapy. Following this success, the company launched two successful IPOs: one on Euronext Brussels in September 2020 and another on NASDAQ in July 2021.
Exciting Updates from Clinical Studies
Recent developments include substantial findings from the BETTER SLEEP study, which led to CE mark approval for expanding therapeutic indications to include patients with Complete Concentric Collapse (CCC). This represents a significant step, as these patients are often excluded from competitor therapies. Additionally, Nyxoah celebrated positive outcomes from the DREAM IDE pivotal study, leading to FDA approval for a specific group of adult patients with moderate to severe OSA.
Connecting with Nyxoah
As Nyxoah continues to break new ground in medical technology and patient care, staying informed about their progress is essential. Interested parties can find detailed information and updates on their official website, which highlights their commitment to innovation and excellence.
Get in Touch
If you have any inquiries or require more information about Nyxoah and their offerings, please reach out to their dedicated team. John Landry, the Chief Financial Officer, and Rémi Renard, the Chief Investor Relations & Corporate Communication Officer, are available for your questions. You can connect with them via email at IR@nyxoah.com.
Frequently Asked Questions
What is the Genio system?
The Genio system is Nyxoah's leadless, battery-free device that provides hypoglossal neurostimulation therapy for obstructive sleep apnea patients.
When will Nyxoah participate in the Piper Sandler conference?
Nyxoah will present during the Piper Sandler 37th Annual Healthcare Conference on December 4.
Where can I access the live presentation?
The presentation will be available via a live audio webcast on Nyxoah’s investor relations page during the conference.
What recent approvals has Nyxoah received?
Nyxoah received CE mark approval for the Genio system's expansion to include patients with Complete Concentric Collapse and FDA approval for certain adult patients.
How can I contact Nyxoah for more information?
You can reach out to Nyxoah’s Chief Financial Officer or Head of Investor Relations at IR@nyxoah.com for inquiries.
